Yeh L C, Betchel K P, Lee J C
Department of Biochemistry, The University of Texas Health Science Center, San Antonio, Texas 78284-7760, USA.
J Bone Miner Res. 1998 Dec;13(12):1870-9. doi: 10.1359/jbmr.1998.13.12.1870.
Osteogenic protein-1 (OP-1 or bone morphogenetic protein-7 [BMP-7]) stimulates osteoblast differentiation in vitro and induces bone formation in vivo. BMPs exert their effects through complex formation with a heterodimeric receptor composed of a type I and a type II polypeptide. In the present study, mRNAs for three BMP subtype I receptors (ActR-I, BMPR-IA, and BMPR-IB) and one BMPR-II receptor were detected by Northern analysis in two human osteosarcoma cell lines (SaOS-2 and TE85) and in the primary cultures of fetal rat calvaria (FRC) cells. OP-1 affected the steady-state mRNA levels of these receptors differently among these cell types. To study the role of each receptor type in OP-1 action in FRC cells, receptor synthesis was inhibited by antisense oligonucleotides. Inhibition of receptor synthesis was confirmed by immunoprecipitation of radiolabeled cellular proteins with specific antibodies. The osteogenic action of OP-1 was measured by alkaline phosphatase (ALP) activity and mineralized bone nodule formation in FRC cells. Results showed that inhibition of synthesis of a single subtype I receptor alone did not affect significantly the OP-1-stimulated ALP activity. Inhibition of BMPR-II synthesis reduced the OP-1-stimulated ALP activity by about 50%. Inhibition of synthesis of any one of the type I receptor plus the BMPR-II receptor did not reduce the OP-1-stimulated ALP activity significantly beyond that observed by inhibition of BMPR-II alone. Under these conditions, nodule formation was affected similarly, thus supporting the observations made with the ALP measurements. The present results suggest that the ActR-I, BMPR-IA, and BMPR-IB receptors and the BMPR-II receptor are expressed and functional for OP-1 in FRC cells and that regulation of synthesis of these receptors may be a mechanism by which a specific cell type responds to OP-1. The turnover rate of these receptor proteins might be relatively long and another type II receptor(s) for OP-1 might be functional in FRC cells.
成骨蛋白-1(OP-1或骨形态发生蛋白-7 [BMP-7])在体外刺激成骨细胞分化,并在体内诱导骨形成。骨形态发生蛋白通过与由I型和II型多肽组成的异二聚体受体形成复合物来发挥其作用。在本研究中,通过Northern分析在两个人骨肉瘤细胞系(SaOS-2和TE85)以及胎鼠颅骨(FRC)细胞的原代培养物中检测到三种BMP I型受体(激活素受体-I [ActR-I]、骨形态发生蛋白受体-IA [BMPR-IA]和骨形态发生蛋白受体-IB [BMPR-IB])和一种BMPR-II受体的mRNA。OP-1在这些细胞类型中对这些受体的稳态mRNA水平产生不同的影响。为了研究每种受体类型在FRC细胞中OP-1作用中的作用,通过反义寡核苷酸抑制受体合成。用特异性抗体对放射性标记的细胞蛋白进行免疫沉淀,证实了受体合成的抑制。通过FRC细胞中的碱性磷酸酶(ALP)活性和矿化骨结节形成来测量OP-1的成骨作用。结果表明,单独抑制单一I型受体的合成对OP-1刺激的ALP活性没有显著影响。抑制BMPR-II合成使OP-1刺激的ALP活性降低约50%。抑制任何一种I型受体加上BMPR-II受体的合成,与单独抑制BMPR-II相比,并没有显著降低OP-1刺激的ALP活性。在这些条件下,结节形成受到类似的影响,从而支持了ALP测量的结果。目前的结果表明,ActR-I、BMPR-IA和BMPR-IB受体以及BMPR-II受体在FRC细胞中表达并对OP-1起作用,并且这些受体合成的调节可能是特定细胞类型对OP-1作出反应的一种机制。这些受体蛋白的周转率可能相对较长,并且FRC细胞中可能存在另一种OP-1的II型受体起作用。